Us Bancorp \De\ Morphic Holding, Inc. Transaction History

Us Bancorp \De\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$19.95 - $31.0 $19,551 - $30,380	980 Added 5444.44%	998 $28,000
Q3 2023 Nov 03, 2023	SELL	$21.33 - $59.42 $60,363 - $168,158	-2,830 Reduced 99.37%	18 $0
Q2 2023 Aug 09, 2023	BUY	$34.33 - $62.11 $97,771 - $176,889	2,848 New	2,848 $163,000
Q2 2022 Aug 01, 2022	SELL	$19.74 - $43.01 $2,487 - $5,419	-126 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$36.25 - $52.02 $4,567 - $6,554	126 New	126 $5,000
Q4 2021 Feb 11, 2022	SELL	$43.27 - $65.72 $5,365 - $8,149	-124 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$53.61 - $67.5 $6,647 - $8,370	124 New	124 $7,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.